Skip to main content
. 2021 May 15;142(3):495–511. doi: 10.1007/s00401-021-02324-0

Table 2.

Demographic and clinical data for final validation cohort

All Samples Control PD MSA (C: P:mixed)
Total samples 154 51 53 50 (33:13:4)
Agea (range) 67.3 ± 9.8 (40–88) 66.6 ± 8.9 (44–88) 72.0 ± 10.2 (40–88) 62.9 ± 7.9 (47–79)
Sex (male:female) 82:72 23:28 33:20 26:24
Disease duration in yearsa (range) 6.9 ± 4.1 (1–26) 8.1 ± 3.8 (2–20) 5.6 ± 4.0 (1–26)
Race/ethnicityb Asc – 8 As – 1 As – 1 As – 6
B – 4 B – 0 B – 0 B – 4
H – 22 H – 10 H – 11 H – 1
HN – 0 HN – 0 HN – 0 HN – 0
NA – 5 NA – 1 NA – 4 NA – 0
ND – 6 ND –4 ND –1 ND –1
W – 109 W – 35 W – 36 W – 38
UPDRSd motor (range) 26.0 ± 13.3 (0–49)
H&Yd (range) 2.3 ± 0.9 (0–5) 2.3 ± 0.8 (0–4) 3.0 ± 2.8 (1–5)
MMSEd (range) 27.6 ± 2.3 (18–30) 28.0 ± 1.7 (24–30)e

aMean ± SD. bAs—Asian; B—Black; H—Hispanic; HN—Hispanic, non-White; NA—Native American, ND—non-disclosed; W—White. cUndefined Asian—8. dUPDRS—Unified Parkinson's disease rating scale, H&Y—Höhn and Yahr rating scale, MMSE—Mini-Mental State Examination. eConverted from Montreal Cognitive Assessment (MoCA) according to Lawton et al. [36]